{
  "id": "opioid",
  "title": "Opioid",
  "lang": "en",
  "source_lang": "en",
  "summary": "Opioids are receptor-active substances used in medicine, especially for pain relief, that can also cause dependence and fatal overdose.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Opioids"
  ],
  "generated_at": "2026-10-13",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/opioid/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/opioid/",
      "json": "https://aiwiki.page/zh/opioid.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "An opioid is a substance that acts on opioid receptors, a group of G protein-coupled receptors involved in pain perception and other physiological processes. Opioids include naturally occurring opium-derived compounds such as morphine, semisynthetic and synthetic drugs, and peptides produced within the body. In medical usage, the term most often denotes drugs with morphine-like effects, particularly relief of pain. “Opioid” is broader than “opiate,” which traditionally refers to substances derived from opium. (who.int)\n\nOpioid medicines have important roles in severe pain management, anesthesia, and palliative care; some also treat opioid use disorder. Their effects and risks vary with receptor activity, drug properties, and clinical circumstances. Adverse effects include constipation, sedation, and respiratory depression, while repeated exposure can produce tolerance and physical dependence. Opioid use disorder is distinct from physical dependence, and overdose can be fatal. These properties connect opioid pharmacology with clinical medicine, addiction treatment, and public health. (who.int)\n\nThe subject encompasses the development of opioid drugs, the endogenous opioid system, mechanisms of action, medical uses, and the consequences of exposure. It also includes the epidemiology of nonmedical use and overdose, regulation, and unequal access to medicines for pain relief. These population-level issues require distinctions between pharmaceutical use and illicit drug supplies, and between inadequate access to treatment and opioid-related harm. (cdc.gov)"
    },
    {
      "heading": "Terminology, Scope, and Classification",
      "text": "In pharmacology, opioid identifies substances by their interaction with opioid receptors, rather than by a single chemical structure or manufacturing method. The broader scientific vocabulary encompasses externally administered compounds and endogenous opioid peptides, including endorphins, enkephalins, and dynorphins. In ordinary clinical usage, however, “opioids” usually means drugs that activate these receptors and produce morphine-like effects, particularly relief of pain. Opioid analgesic is therefore a narrower functional designation than opioid-receptor ligand: the latter also encompasses substances that bind to receptors without activating them. WHO’s clinical definition includes compounds extracted from the opium poppy and semisynthetic and synthetic compounds with similar receptor-mediated properties. (doi.org)\n\nOpiate, in its narrower traditional usage, refers to naturally occurring opium alkaloids, especially morphine and codeine. Opioid is the more inclusive term and does not require a substance to originate in opium. Usage is not completely uniform: some publications also call semisynthetic opium derivatives “opiates,” so the intended scope must be distinguished from the stricter natural-compound definition. Narcotic is less precise. Historically associated with stupor and the dulling of sensation, it has been applied to opioids but also used loosely for drugs more generally. It does not specify a receptor target, molecular structure, or degree of receptor activation, making it unsuitable as an exact pharmacological synonym. (drugabuse.gov)\n\nClassification by origin divides exogenous opioids—substances introduced from outside the body—into three conventional groups. Natural opioids, such as morphine and codeine, occur in the opium poppy, Papaver somniferum. Semisynthetic opioids are produced by chemically modifying naturally occurring opium compounds; examples include oxycodone, heroin, hydrocodone, and hydromorphone. Synthetic opioids, including fentanyl, methadone, and meperidine, are manufactured through chemical synthesis rather than modification of an extracted opium alkaloid. These categories describe chemical origin, not whether a drug is medically authorized, how strongly it activates a receptor, or how it is supplied. The DEA’s 2024 resource guide uses this three-part distinction. (dea.gov)\n\nClassification by receptor action instead distinguishes full agonists, partial agonists, and antagonists. At the μ-opioid receptor, morphine is conventionally classified as a full agonist, capable of producing the maximal response of the receptor system being examined. Buprenorphine is a partial agonist: it binds with high affinity but has lower intrinsic activating efficacy, so strong binding does not imply full activation. An antagonist, exemplified by naloxone, blocks agonist action rather than producing the same activating response. These descriptions concern action at a specified receptor; they are not measures of chemical origin or interchangeable labels for clinical effectiveness. Naloxone consequently belongs within opioid-receptor pharmacology but is not an opioid analgesic. (pharmacologyeducation.org)\n\nPharmacological identity is also distinct from legal status and production conditions. Pharmaceutical fentanyl and illicitly manufactured fentanyl can contain the same active compound; “illicit” does not designate a different receptor mechanism. In the United States, authorized fentanyl products include injectable formulations, transdermal patches, and transmucosal preparations. Clandestinely produced fentanyl is also distributed as powder or in counterfeit tablets, alone or mixed with other substances. The distinction concerns manufacturing controls, formulation, distribution, and regulatory oversight, rather than membership in separate pharmacological classes. Fentanyl analogues, by contrast, are chemically related but distinct compounds and should not automatically be treated as identical to fentanyl itself. (fof.dea.gov)"
    },
    {
      "heading": "Historical Development of Opioid Medicines and Research",
      "text": "Before the nineteenth century, opioid medicines chiefly consisted of opium and preparations such as laudanum, an alcoholic tincture containing a mixture of poppy alkaloids. In the early 1800s, the German apothecary Friedrich Wilhelm Sertürner isolated morphine from opium and named it “morphium” after Morpheus, the Greek god of dreams. Separating an active compound from the plant extract made it possible to formulate medicines around a chemically identifiable ingredient rather than the mixture as a whole—a key step toward reproducible strength and dosing. In 1832, the French chemist Pierre-Jean Robiquet isolated codeine, another opium alkaloid, which subsequently became a medicine for pain relief and cough suppression. Morphine and codeine thus established an approach in which individual constituents, rather than crude opium alone, could be manufactured and investigated as drugs. (cen.acs.org)\n\nChemical modification of these alkaloids opened a second route to opioid medicines. Heroin, or diacetylmorphine, was first synthesized from morphine in 1874; Bayer introduced it for medical use in 1898, including as a pain reliever and cough suppressant. The distinction between discovery and pharmaceutical introduction is important: its first synthesis preceded commercial medical use by 24 years. Subsequent semisynthetic medicines included oxycodone, produced from the opium alkaloid thebaine, and hydrocodone, first synthesized from codeine in Germany in 1920 by Carl Mannich and Helene Löwenheim. Fully synthetic compounds, including meperidine and methadone, extended opioid drug development beyond chemical modification of extracted poppy alkaloids. In 1959, Paul Janssen developed fentanyl, a fully synthetic opioid intended as an intravenous surgical analgesic, placing it within this expanding tradition of laboratory-designed medicines for pain and anesthesia. (museum.dea.gov)\n\nDirect experimental evidence for opioid recognition sites emerged in 1973. Candace Pert and Solomon Snyder reported that tritium-labelled naloxone bound specifically to sites in mammalian brain and guinea-pig intestine; the ability of other opioid drugs to compete for those sites closely paralleled their pharmacological potency. Independently, Eric Simon, Jean Hiller, and Isidore Edelman demonstrated stereospecific, saturable binding of labelled etorphine in rat-brain homogenates, while Lars Terenius investigated stereoselective binding in rat-brain synaptic membrane preparations. These experiments converted receptor hypotheses into measurable biochemical evidence. Saturation indicated a finite population of binding sites, competition connected binding with drug action, and discrimination between optical isomers supported selective molecular recognition rather than indiscriminate association with tissue. The assays demonstrated recognition sites without yet establishing their complete molecular structures. (pubmed.ncbi.nlm.nih.gov)\n\nThe identification of naturally occurring receptor ligands followed two years later. On December 18, 1975, John Hughes, Hans Kosterlitz, and colleagues published the structures of methionine-enkephalin and leucine-enkephalin, two brain-derived pentapeptides with potent opiate agonist activity. Each contained five amino-acid residues: Tyr–Gly–Gly–Phe–Met and Tyr–Gly–Gly–Phe–Leu, respectively. Their structural assignments rested on amino-acid sequencing using the dansyl–Edman procedure and mass spectrometry, followed by synthesis and comparison of the artificial peptides with the natural material. This supplied chemically defined endogenous ligands for sites previously studied mainly through administered drugs: opioid receptors participated in an internal signaling system, rather than existing solely as targets for plant alkaloids or synthetic medicines. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Opioid Receptors and Endogenous Signaling",
      "text": "The three classical opioid receptor classes are μ (mu), δ (delta), and κ (kappa), also designated MOP, DOP, and KOP; MOR, DOR, and KOR are common alternative abbreviations. They are G protein-coupled receptors with seven membrane-spanning segments. A fourth, related receptor recognizes nociceptin/orphanin FQ and is designated NOP, formerly ORL1. Although structurally related to the classical receptors, NOP has a distinct ligand profile: nociceptin/orphanin FQ is its principal endogenous agonist, whereas classical opioid peptides have little activity at it. Conversely, nociceptin does not efficiently activate μ, δ, or κ receptors. The classical receptors are sensitive to the antagonist naloxone, while NOP-mediated responses are relatively insensitive to it. (doi.org)\n\nThe principal endogenous opioid peptide families arise through enzymatic cleavage of larger precursor proteins. Proenkephalin, encoded by PENK, yields methionine-enkephalin and leucine-enkephalin, each containing five amino acids, together with longer enkephalin-containing peptides. Pro-opiomelanocortin (POMC) yields β-endorphin and several nonopioid hormones; prodynorphin (PDYN) yields dynorphin A, dynorphin B, and related peptides. These families have overlapping rather than exclusive receptor preferences: enkephalins activate δ and μ receptors, β-endorphin acts prominently at μ and δ receptors, and dynorphins preferentially activate κ receptors. Tissue-specific precursor processing therefore influences which active peptides are available, not merely how much precursor is expressed. Nociceptin/orphanin FQ belongs to a separate precursor system encoded by PNOC. (govinfo.gov)\n\nOpioid receptors and peptide-producing cells are distributed unevenly throughout the central nervous system. Relevant sites include the spinal dorsal horn, brainstem pain-control regions such as the periaqueductal gray, and forebrain structures involved in sensory and affective processing. Receptors also occur on peripheral sensory nerve terminals and in the gastrointestinal tract, including enteric neurons. This distribution permits opioid signaling to influence both ascending nociceptive input and local intestinal functions. Peripheral signaling is not simply an extension of peptide release in the brain: in inflamed tissue, infiltrating immune cells can supply opioid peptides directly to nearby sensory nerves. In 1990, Christoph Stein and colleagues demonstrated this arrangement in rats with paw inflammation; blocking local opioid peptides or receptors reduced the experimentally induced antinociceptive response. (govinfo.gov)\n\nEndogenous signaling depends on peptide synthesis, storage, stimulus-dependent release, and enzymatic degradation. Peptides can be stored in dense-core vesicles and released near receptor-bearing cells; peptidases restrict their persistence and access to receptors. In rat spinal-cord experiments published in 2003, peptidase inhibition enabled endogenously released opioids to produce detectable μ-receptor internalization in dorsal-horn neurons, illustrating how degradation can limit receptor activation. Administered opioid drugs need not reproduce this spatially and temporally restricted exposure. Ligand identity also affects receptor handling: a 2003 study of guinea-pig enteric neurons found that methionine-enkephalin and fentanyl induced rapid μ-receptor internalization, whereas morphine did not under the same experimental conditions. (pubmed.ncbi.nlm.nih.gov)\n\nThe endogenous system participates in pain modulation, gastrointestinal regulation, and processes involving stress and reward, but its effects depend on receptor subtype, anatomical location, and physiological context. Human evidence for pain modulation includes Jon-Kar Zubieta and colleagues’ 2005 molecular-imaging study: a placebo presented with an expectation of analgesia increased endogenous μ-opioid activity in regions including the anterior cingulate cortex, insula, and nucleus accumbens, alongside reduced pain ratings. Such receptor-level measurements do not identify a single released peptide or establish that one peptide uniquely produces an emotion. They demonstrate recruitment of an opioid signaling system within interacting neural circuits. (guidetopharmacology.org)"
    },
    {
      "heading": "Molecular and Circuit Mechanisms of Drug Action",
      "text": "Opioid receptors are G-protein-coupled receptors that predominantly signal through inhibitory \\(G_{i/o}\\) proteins. Agonist binding promotes exchange of GDP for GTP on the G-protein α subunit, enabling α and βγ components to regulate intracellular effectors. Activated \\(G_{\\alpha i}\\) inhibits adenylyl cyclase, reducing production of cyclic AMP and downstream cAMP-dependent signaling. In parallel, \\(G_{\\beta\\gamma}\\) can inhibit voltage-gated calcium channels and activate G-protein-gated inwardly rectifying potassium channels, or GIRKs. These are partly parallel mechanisms: rapid channel modulation need not result from a prior decrease in cAMP. Reduced calcium entry at presynaptic terminals decreases neurotransmitter release, while increased potassium conductance moves the membrane potential toward the potassium equilibrium potential, generally hyperpolarizing the neuron and reducing firing. The contribution of each mechanism depends on the cell’s receptors, channels, and signaling machinery. (pmc.ncbi.nlm.nih.gov)\n\nAnalgesia arises at peripheral, spinal, and supraspinal sites. At peripheral sensory endings, μ-receptor activation can suppress excitation and calcium signaling: Landon Baillie, Helmut Schmidhammer, and Sean Mulligan demonstrated inhibition of N-type calcium-channel signaling in identified CGRP-containing nociceptive terminals in 2015. In the spinal dorsal horn, opioids inhibit transmitter release from primary afferents and reduce the excitability of postsynaptic neurons, limiting onward transmission of nociceptive information. Experiments reported in 2010 linked μ-receptor inhibition of the N-type calcium channel \\(Ca_V2.2\\) to spinal morphine analgesia and showed that alternative splicing of the channel changes its sensitivity to opioid modulation. These findings connect receptor activation to specific ion-channel mechanisms rather than treating analgesia as a uniform suppression of nervous-system activity. (sciencedirect.com)\n\nAbove the spinal cord, inhibition of an inhibitory neuron can increase activity in its downstream targets—a circuit effect called disinhibition. In the periaqueductal gray, reduced GABA release can recruit descending antinociceptive pathways that influence spinal processing through brainstem relays, including the rostral ventromedial medulla. Christopher Vaughan and MacDonald Christie’s 1997 rat-slice experiments showed that methionine-enkephalin reduced evoked GABAergic synaptic currents by 57%; excitatory currents were also inhibited, demonstrating that the circuit action is more complex than disinhibition alone. Reduced nociceptive transmission is distinct from reduced unpleasantness or aversion associated with pain. A 2005 rat study of opioid activation in the anterior cingulate cortex demonstrated selective modulation of pain-related aversion, supporting a separation between sensory and affective effects. (onlinelibrary.wiley.com)\n\nThe same inhibitory mechanisms operate outside pain pathways. μ-Receptor activation suppresses components of respiratory-control networks, including the medullary pre-Bötzinger complex and pontine parabrachial/Kölliker-Fuse region. In a 2021 experiment involving 48 artificially ventilated, decerebrate rabbits, remifentanil reduced median respiratory rate from 36 to 16 breaths per minute; local antagonist injections produced only partial recovery, indicating contributions from multiple network sites. In the intestine, inhibition of enteric transmitter release disrupts coordinated propulsive contractions, providing a mechanism for slowed transit and constipation. In reward circuitry, inhibition can instead increase downstream activity: Steven Johnson and R. Alan North showed in 1992 that μ-receptor agonists hyperpolarized GABA-containing interneurons in rat ventral tegmental slices, reducing inhibitory input to dopamine neurons. This disinhibition provides one mechanism contributing to opioid reinforcement. (pmc.ncbi.nlm.nih.gov)\n\nReceptor affinity, potency, and intrinsic efficacy describe different properties. Affinity concerns binding strength; potency describes the concentration or dose required for a specified response, often expressed as \\(EC_{50}\\); intrinsic efficacy concerns a bound ligand’s capacity to activate signaling. Receptor occupancy therefore does not directly determine response magnitude: receptor abundance and signal amplification can allow a maximal response before all receptors are occupied, producing a receptor reserve. Partial agonists have lower intrinsic efficacy and may produce a lower maximum response in a given system despite extensive occupancy. In 2024, Jun Zhao and colleagues compared nine μ-receptor ligands and linked their differing efficacies—including low-efficacy buprenorphine and higher-efficacy morphine—to different receptor conformational populations. Greater potency means that less drug is needed for a defined effect, not necessarily stronger maximal analgesia or greater clinical benefit; analgesic and adverse-effect pathways must be considered separately. (ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Pharmacokinetics, Formulations, and Individual Variation",
      "text": "Administration route and formulation determine how rapidly an opioid enters the circulation and how much reaches it unchanged. Oral morphine undergoes substantial presystemic, or first-pass, metabolism: its oral bioavailability is below 40%, with considerable variation between individuals. Intravenous injection bypasses gastrointestinal absorption and first-pass metabolism, whereas intramuscular injection still requires absorption from the injection site. Immediate-release and extended-release oral preparations contain the same active drug but deliver it at different rates; extended-release morphine slows drug release rather than fundamentally changing the molecule’s elimination mechanism. Thus, formulation can prolong exposure without increasing the drug’s intrinsic potency. (dailymed.nlm.nih.gov)\n\nTransdermal and transmucosal products produce distinct absorption profiles. Fentanyl patches deliver drug through the skin over a nominal 72-hour application period. After initial application, serum concentrations generally level off between 12 and 24 hours; residual fentanyl in the skin continues to enter the circulation after patch removal, with concentrations falling by approximately half over 20–27 hours. External heat can increase absorption. Oral transmucosal fentanyl, by contrast, combines relatively rapid absorption across the cheek lining with slower gastrointestinal absorption of the swallowed portion. For the ACTIQ lozenge specifically, approximately 25% of the total dose becomes systemically available directly through the buccal mucosa, and another approximately 25% through the swallowed fraction after first-pass metabolism, giving overall bioavailability near 50%. These proportions are formulation-specific, not universal properties of fentanyl. (dailymed.nlm.nih.gov)\n\nDistribution and elimination also separate the duration of analgesia from the time required to clear a drug. Fentanyl distributes rapidly into tissues and accumulates in skeletal muscle and fat, from which it can return slowly to the circulation. Methadone provides a particularly clear distinction: product labeling reports analgesia lasting 4–8 hours in single-dose studies, but a plasma elimination half-life of 8–59 hours across studies. Repeated administration can therefore produce accumulation even when pain relief from an earlier dose has diminished. The 2022 United States CDC guideline likewise notes that methadone’s peak respiratory-depressant effect can occur later and last longer than its peak analgesic effect. Elimination half-life is consequently not a direct measure of either analgesic duration or the duration of every adverse effect. (dailymed.nlm.nih.gov)\n\nHepatic metabolism may inactivate an opioid or generate metabolites that contribute to its effects. The enzyme CYP2D6 converts codeine to morphine; inherited differences in the CYP2D6 gene alter this conversion. Poor metabolizers form substantially less morphine and commonly obtain less analgesia, whereas ultrarapid metabolizers can develop unusually high morphine exposure. The 2021 Clinical Pharmacogenetics Implementation Consortium guideline reported that, in healthy-volunteer studies, ultrarapid metabolizers had a 45% higher median plasma morphine area under the concentration–time curve than normal metabolizers, while emphasizing substantial variation within genotype groups. Morphine itself undergoes glucuronidation, producing morphine-3-glucuronide and morphine-6-glucuronide. The latter has analgesic activity; the former has no significant analgesic activity. Both are principally eliminated through the kidneys. (pmc.ncbi.nlm.nih.gov)\n\nOrgan function, age, and interacting medicines further modify exposure. Renal failure can increase morphine exposure and allow its glucuronide metabolites to accumulate; cirrhosis reduces morphine clearance and prolongs its half-life. Older adults more frequently have reduced renal or hepatic function, narrowing the margin between effective exposure and toxicity. Drug interactions are pathway-dependent: CYP3A4 inhibitors can increase fentanyl concentrations, whereas enzyme inducers can reduce them; CYP2D6 inhibitors can reduce codeine’s conversion to morphine. Such interactions affect drug concentrations or metabolite formation and are distinct from additive sedation caused by combining central nervous system depressants. (dailymed.nlm.nih.gov)\n\nMorphine milligram equivalents (MME) express opioid quantities on an approximate common comparison scale. They are useful for describing exposure in clinical records and population studies, but do not establish that different opioids or formulations are interchangeable. The CDC’s 2022 guideline explicitly characterizes equianalgesic conversions as estimates that cannot capture individual genetic and pharmacokinetic variation. Incomplete cross-tolerance further limits equivalence when exposure changes from one opioid to another, and methadone’s variable elimination makes simple conversion particularly problematic. MME therefore does not represent a universally equivalent concentration, clinical effect, or replacement dose. (cdc.gov)"
    },
    {
      "heading": "Medical Uses and Evidence of Benefit",
      "text": "Opioid analgesics have an established role in severe acute pain, including pain from crush injuries, burns, and major surgery. These settings differ from persistent noncancer pain: treatment addresses an injury or operation and the associated recovery period, rather than an indefinitely continuing condition. The 2022 United States CDC guideline identifies severe trauma and invasive surgery as important settings for opioid therapy, while finding that opioids are not more effective than nonopioid treatments for many common acute conditions. Analgesic benefit therefore depends on the clinical context; effectiveness after major surgery does not establish superiority for uncomplicated musculoskeletal or dental pain. (cdc.gov)\n\nIn anesthesia, opioids provide an analgesic component of perioperative care rather than merely treating pain after the procedure. The United States prescribing information for fentanyl citrate injection includes short-duration analgesia during anesthetic premedication, induction, maintenance, and immediate postoperative recovery, as well as supplementation of general or regional anesthesia. It also includes use with oxygen as an anesthetic agent in selected high-risk operations, such as open-heart surgery. These indications concern a monitored procedural setting and specific injectable formulations; they are distinct from continuing outpatient treatment of chronic pain. (accessdata.fda.gov)\n\nFor moderate-to-severe cancer pain, morphine, oxycodone, hydromorphone, and other opioids are established analgesic options. The National Cancer Institute’s evidence review reports that most participants in studies of oral morphine obtained substantial relief, while a 2022 review found no clear difference in analgesic effectiveness between oxycodone and other strong opioids. Cancer pain treatment can combine opioids with nonopioid medicines, radiotherapy for painful lesions, or other disease-directed interventions. In palliative care, symptom relief and preservation of quality of life are central goals; at the end of life, immediate comfort can take precedence over longer-term functional outcomes. Opioids are commonly used for pain in the final hours of life. Evidence from these settings is not interchangeable with evidence from trials of persistent noncancer pain, which examine different populations, time horizons, and outcomes. (cancer.gov)\n\nSelected opioids also have nonanalgesic indications, notably suppression of cough. Codeine-containing preparations may contain codeine alone or combine it with other ingredients, and authorization differs by product and jurisdiction. On January 11, 2018, the United States FDA announced labeling changes restricting prescription cough-and-cold products containing codeine or hydrocodone to adults aged 18 years or older. In the European Union, measures adopted in April 2015 contraindicated codeine for cough and cold below age 12 and made it not recommended for adolescents aged 12–18 with compromised respiratory function. The European review also found limited evidence of effectiveness for cough in children. These are indication-specific restrictions, not evidence that every opioid preparation has the same approved uses. (fda.gov)\n\nFor persistent noncancer pain, short-term analgesic efficacy is better established than sustained improvement in function or quality of life. The evidence synthesis supporting the 2022 CDC guideline found a small average reduction in pain intensity versus placebo over one to less than six months: 0.79 points on a 0–10 scale, accompanied by small functional improvements. Benefits diminished with longer follow-up, and placebo-controlled evidence at six months or beyond was lacking. Pain scores alone therefore do not demonstrate durable improvement in daily activity. Multimodal care combines pharmacological treatment with approaches such as exercise, psychological therapies, and rehabilitation, addressing outcomes beyond analgesia. (cdc.gov)\n\nA direct longer-term comparison was provided by Erin Krebs and colleagues’ 2018 SPACE randomized controlled trial. It enrolled 240 patients with chronic back pain or hip or knee osteoarthritis pain and compared stepped opioid and nonopioid medication strategies over 12 months. Mean Brief Pain Inventory interference scores at 12 months were 3.4 in the opioid group and 3.3 in the nonopioid group, with no significant difference in pain-related function; medication-related symptoms were more frequent with opioids. This trial addressed particular chronic musculoskeletal conditions and treatment strategies, rather than severe postoperative or cancer pain, and illustrates why evidence of short-term pain relief cannot by itself establish long-term functional benefit. (jamanetwork.com)"
    },
    {
      "heading": "Adverse Effects, Interactions, and Special Populations",
      "text": "Common adverse effects include constipation, nausea, vomiting, pruritus (itching), dizziness, and sedation. Their frequency depends on the drug, dose, formulation, previous exposure, and population studied; percentages from separate trials cannot establish a reliable ranking of opioid safety. In placebo-controlled trials reported in the October 2021 OxyContin extended-release oxycodone label, 227 treated participants experienced constipation, nausea, and somnolence at rates of 23% each, compared with 7%, 11%, and 4%, respectively, among 45 placebo recipients. Dizziness and pruritus each occurred in 13%, and vomiting in 12%, of treated participants. Constipation reflects decreased propulsive intestinal contractions and increased smooth-muscle tone, rather than simply reduced activity or food intake. (accessdata.fda.gov)\n\nRespiratory depression is a potentially fatal adverse effect that can occur even with medically directed use, particularly when treatment begins or the dose increases. Opioids reduce the responsiveness of brainstem respiratory centers to rising carbon dioxide concentrations; resulting carbon dioxide retention can further intensify sedation. (accessdata.fda.gov) Concurrent benzodiazepines, alcohol, or other central nervous system depressants can compound sedation and impaired breathing, producing coma or death. On August 31, 2016, the United States Food and Drug Administration (FDA) announced boxed-warning requirements for combined opioid and benzodiazepine exposure, covering nearly 400 products. (fda.gov) Other relevant combinations include sedative-hypnotics, muscle relaxants, and sedating anticonvulsants such as gabapentin and pregabalin. The CDC’s 2022 evidence review identified an observational study in which concurrent benzodiazepine prescribing was associated with almost four times the risk of overdose death compared with opioid prescribing alone; this association is not a uniform risk multiplier for every patient or combination. (cdc.gov)\n\nOlder adults have additional vulnerabilities because reduced medication clearance, multiple illnesses, and concurrent medicines can narrow the margin between analgesia and toxicity. Sedation, confusion, and impaired balance contribute to concerns about falls; pre-existing cognitive impairment also increases the likelihood of medication errors. The CDC’s 2022 guideline specifically identifies these concerns in adults aged 65 years or older. Sleep apnea was associated with increased risk of life-threatening respiratory or central nervous system depression or overdose in a case-control analysis of veterans receiving opioids. (cdc.gov) Product labeling also identifies chronic obstructive pulmonary disease, reduced respiratory reserve, hypoxia, and pre-existing carbon dioxide retention as factors increasing susceptibility to breathing complications, including at recommended doses. (accessdata.fda.gov)\n\nOpioids cross the placenta, exposing the fetus during pregnancy, and exposure around delivery can cause neonatal sedation and respiratory depression. Prolonged prenatal exposure can also produce physical dependence, followed after birth by neonatal opioid withdrawal syndrome. Manifestations include irritability, abnormal sleep, a high-pitched cry, tremor, vomiting, diarrhea, and inadequate weight gain. Its onset and severity vary with the opioid, duration of exposure, timing of the last maternal dose, and the newborn’s elimination of the drug. This withdrawal syndrome is distinct from the immediate respiratory-depressant effects of an opioid still present in the newborn’s circulation. (fda.gov)\n\nPediatric and breastfeeding restrictions are drug- and product-specific. On April 20, 2017, the FDA announced contraindications for codeine used for pain or cough and tramadol used for pain in children younger than 12 years, and for tramadol after tonsil or adenoid surgery in those younger than 18; codeine already carried the latter restriction. The announcement also strengthened warnings against breastfeeding during codeine or tramadol use because infant exposure through milk can cause excessive sleepiness and serious breathing problems. Rapid codeine conversion to morphine is a particular source of unpredictable exposure. (fda.gov) On January 11, 2018, the FDA separately restricted prescription cough-and-cold medicines containing codeine or hydrocodone to adults aged 18 years and older. These restrictions concern specified products and indications, rather than a single age prohibition applying to all opioid medicines. (fda.gov)"
    },
    {
      "heading": "Tolerance, Physical Dependence, and Withdrawal",
      "text": "Tolerance is a reduction in a drug’s effect after repeated exposure: the same dose produces a smaller response, or a larger dose is required to reproduce a previously obtained effect. Physical dependence is an adaptation in which declining opioid exposure or interruption of receptor activation produces withdrawal. These phenomena are distinct and can develop during medically supervised treatment; neither alone establishes opioid use disorder. The CDC’s 2022 guideline specifies that tolerance and withdrawal do not count toward the relevant DSM-5 diagnostic criteria when opioids are taken solely under appropriate medical supervision. Opioid use disorder instead involves a clinically significant pattern of problematic use, including features such as impaired control and continued use despite harm. (fda.gov)\n\nDependence reflects compensatory changes in opioid-responsive cells and circuits, rather than simply the persistence of a drug in the body. A well-studied example involves noradrenergic neurons in the locus coeruleus. Acute opioid exposure inhibits their activity, whereas repeated exposure recruits adaptations that counteract this inhibition. In a 1997 experimental study, chronic morphine administration increased components of the cyclic AMP signaling pathway, including particular forms of adenylyl cyclase and cyclic AMP-dependent protein kinase. Manipulating the transcription factor CREB provided evidence for its contribution to these adaptations. After opioid inhibition is removed, the adapted system can become overactive, contributing to withdrawal. This experimental model explains part of the syndrome, not every manifestation of human dependence. (pubmed.ncbi.nlm.nih.gov)\n\nTolerance is effect-specific: adaptation to analgesia does not establish equivalent protection against respiratory depression. Its development also depends on the drug and exposure pattern. Rob Hill and colleagues reported in a mouse study published in 2016 that tolerance to morphine’s respiratory effects developed more slowly than tolerance to its antinociceptive effects. Human experimental evidence likewise demonstrates that respiratory tolerance is incomplete. A 2021 model-based study estimated that the fentanyl concentration required to reduce ventilation by 50% was approximately 4.3 times higher in chronic high-dose opioid users than in opioid-naïve participants; nevertheless, tolerance did not eliminate susceptibility to respiratory depression. These findings distinguish a shifted dose–response relationship from immunity to overdose. (pubmed.ncbi.nlm.nih.gov)\n\nWithdrawal combines autonomic, gastrointestinal, and psychological manifestations. Signs include sweating, tearing, a runny nose, yawning, dilated pupils, gooseflesh, tremor, and increased heart rate; symptoms include abdominal cramps, nausea, vomiting, diarrhea, muscle aches, anxiety, restlessness, insomnia, and increased pain. Timing varies with the opioid and its duration of action. SAMHSA’s Treatment Improvement Protocol 63 gives approximate early-onset intervals of 8–24 hours after the last use of short-acting opioids, with later onset for long-acting drugs. Spontaneous withdrawal follows declining exposure after cessation or dose reduction. Precipitated withdrawal follows a more abrupt reduction in receptor activation—for example, when naloxone blocks opioid receptors in a physically dependent person. Partial agonists such as buprenorphine can also precipitate withdrawal when they replace a full agonist under particular exposure conditions. (cdc.gov)\n\nTolerance can diminish after reduced exposure or abstinence, making a formerly tolerated amount more hazardous when use resumes. WHO identifies resumption after abstinence, including after detoxification or release from imprisonment, as an overdose risk. Increased pain also requires distinctions among reduced analgesic effectiveness from tolerance, withdrawal-associated pain, progression of the underlying condition, and opioid-induced hyperalgesia, in which opioid exposure itself increases pain sensitivity. These mechanisms can produce overlapping clinical presentations. On April 13, 2023, the FDA announced new labeling warnings concerning opioid-induced hyperalgesia, explicitly distinguishing it from tolerance and withdrawal while noting the difficulty of recognizing it. Worsening pain alone therefore does not establish which mechanism is responsible. (who.int)"
    },
    {
      "heading": "Opioid Use Disorder and Its Treatment",
      "text": "Opioid use disorder (OUD) is a problematic pattern of opioid use causing clinically significant impairment or distress. Its defining features include impaired control over consumption, craving, unsuccessful attempts to reduce use, and continued use despite physical, psychological, or interpersonal harm. Under the DSM-5 framework, diagnosis requires at least two of eleven criteria within twelve months; two or three indicate mild disorder, four or five moderate disorder, and six or more severe disorder. Tolerance and withdrawal are not counted as diagnostic criteria when opioids are taken solely under appropriate medical supervision. Consequently, physical dependence during treatment for pain does not, by itself, establish OUD; the broader pattern of behavior and impairment distinguishes the disorder from expected physiological adaptation. (cdc.gov)\n\nMethadone, buprenorphine, and naltrexone provide three pharmacologically distinct approaches to treatment. Methadone is a full opioid-receptor agonist whose sustained action suppresses withdrawal and reduces craving. Buprenorphine is a partial agonist at the μ-opioid receptor: it binds with high affinity but activates the receptor less strongly than full agonists. It also reduces withdrawal and craving; its ability to displace other agonists explains why initiation can precipitate withdrawal under some exposure conditions. Naltrexone is an antagonist that blocks opioid-receptor activation rather than providing agonist stimulation. Its initiation requires prior clearance of opioids to avoid precipitated withdrawal. Maintenance treatment supplies ongoing pharmacological support, whereas detoxification addresses the withdrawal episode. Detoxification alone does not provide equivalent protection against return to opioid use, overdose, or overdose death. (irp.nida.nih.gov)\n\nTreatment studies assess retention in care, nonmedical opioid consumption, overdose, mortality, and functioning rather than withdrawal relief alone. A 2017 meta-analysis by Luis Sordo and colleagues included nineteen cohorts, following 122,885 people treated with methadone and 15,831 treated with buprenorphine. Pooled all-cause mortality rates during and outside methadone treatment were 11.3 and 36.1 deaths per 1,000 person-years, respectively; corresponding buprenorphine rates were 4.3 and 9.5. Overdose mortality was also lower during treatment. These observational comparisons support an association between retention and lower mortality, but differences between the patient populations prevent interpreting the figures as a direct comparison of the two medicines. Mortality risk was particularly elevated shortly after treatment cessation. (bmj.com)\n\nBehavioral and psychosocial services address aspects of care not resolved by receptor pharmacology, including coping skills, coexisting mental health conditions, housing difficulties, and engagement with continuing treatment. Counseling, psychiatric care, and case management can be integrated with medication provision. Research in federally qualified health centers has linked onsite counseling and psychiatric medication with improved buprenorphine retention, although such associations do not establish that every patient requires the same service package. Clinical guidance distinguishes offering psychosocial care from making it a prerequisite: unavailable or declined counseling is not a reason to withhold or delay medication treatment. (nida.nih.gov)\n\nDelivery settings include specialized opioid treatment programs, primary care, and emergency departments. In the United States, ongoing methadone treatment for OUD is generally provided through certified opioid treatment programs, while buprenorphine can be prescribed in office-based care. The Consolidated Appropriations Act, 2023 removed the separate federal buprenorphine prescribing waiver and its associated patient caps; this change did not alter methadone’s treatment framework. Emergency departments can initiate medication and connect patients with outpatient follow-up. In Gail D’Onofrio and colleagues’ 2015 randomized trial of 329 patients, 78% of those receiving emergency-department-initiated buprenorphine were engaged in treatment after thirty days, compared with 37% receiving referral alone and 45% receiving a brief intervention with facilitated referral. Documented obstacles to access and continuity include stigma, insufficient clinical training, fragmented referral systems, insurance restrictions, treatment costs, transportation difficulties, and competing work or childcare obligations. (samhsa.gov)"
    },
    {
      "heading": "Overdose and Clinical Toxicology",
      "text": "Opioid poisoning is characterized principally by depressed consciousness and impaired ventilation. Activation of opioid receptors in the brain suppresses respiratory drive, producing slow, shallow breathing or complete cessation of breathing. Inadequate ventilation leads to oxygen deficiency, or hypoxia, and can progress to brain injury, cardiac arrest, and death. Pinpoint pupils, unconsciousness, and breathing difficulty form the classical overdose triad, but all three findings need not be present. A 1994 hospital study found the complete triad in only two patients classified as having narcotic overdose on the basis of an immediate response to naloxone. Pupil size therefore cannot independently establish or exclude the diagnosis; impaired breathing is the central life-threatening feature. (who.int)\n\nToxicity depends on the amount reaching the circulation, the speed of absorption, the duration of exposure, and the person’s tolerance and capacity to eliminate the drug. Rapid delivery can produce abrupt respiratory depression, whereas extended-release preparations can prolong exposure. Reduced tolerance after abstinence—for example, following treatment or release from imprisonment—increases the danger of returning to a previously used amount. Concurrent alcohol, benzodiazepines, or other respiratory depressants further increase risk. Pharmaceutical poisoning can follow excessive dosing, administration errors, or accidental ingestion despite a product’s standardized composition. Illicit products introduce additional uncertainty: fentanyl may be present in heroin, cocaine, or counterfeit tablets without the consumer’s knowledge, so the apparent identity or quantity of a product does not reliably specify its opioid content. (pmc.ncbi.nlm.nih.gov)\n\nNaloxone reverses opioid effects by competitively occupying opioid receptor sites rather than activating them. Its established emergency role is reversal of opioid-induced respiratory and central nervous system depression; injectable and intranasal formulations are available. Reversal is not necessarily permanent: an opioid can remain active after naloxone’s antagonist effect diminishes, allowing respiratory depression to recur after an initial improvement. The 2023 United States prescribing information for Narcan nasal spray explicitly identifies this risk and describes repeated administration and continued surveillance. It also notes that reversal of buprenorphine-associated respiratory depression may be incomplete and require larger or repeated antagonist doses. In physically dependent patients, rapid receptor antagonism can precipitate acute withdrawal. (who.int)\n\nProfessional assessment combines airway management and assisted ventilation with antagonist treatment and repeated evaluation of breathing and consciousness. Respiratory support addresses the immediate failure of ventilation rather than waiting for drug elimination; naloxone does not replace comprehensive emergency care. Observation after an apparent response is important because recurrent toxicity may emerge as antagonist activity wanes. The World Health Organization’s 2014 community-management guideline treats bystander naloxone as an interim emergency response, while its overdose guidance identifies airway management, assisted ventilation, and continued observation until full recovery as components of care. (who.int)\n\nToxicology testing supplies evidence of exposure, not a direct measure of poisoning severity. The United States CDC’s 2022 prescribing guideline explains that routine urine “opiate” immunoassays generally detect morphine, which may reflect morphine, codeine, or heroin exposure, but do not detect fentanyl or methadone; oxycodone and buprenorphine may also require separate assays. Consequently, a negative routine screen does not exclude clinically important opioid poisoning. Conversely, a positive urine result does not establish the amount taken, the dose, or whether the detected substance explains the current presentation. Targeted testing and confirmatory gas or liquid chromatography–mass spectrometry can clarify particular exposures, but results must be interpreted alongside the clinical examination rather than substituted for assessment of breathing and consciousness. (cdc.gov)"
    },
    {
      "heading": "Population Health, Regulation, and Access",
      "text": "Opioid epidemiology distinguishes medicine dispensing, nonmedical use, opioid use disorder, and overdose mortality because these indicators measure different phenomena. Dispensing rates count prescriptions rather than individual patients: CDC estimated 125.5 million retail-pharmacy opioid prescriptions in the United States in 2023, or 37.5 prescriptions per 100 residents. Repeated prescriptions for one patient therefore contribute multiple records. Population surveys estimate the prevalence of use and disorder over specified periods. The 2023 National Survey on Drug Use and Health classified prescription pain-reliever misuse as use without one’s own prescription or use other than directed, including excessive dosage or frequency—even when the purpose was pain relief. Its opioid-use-disorder estimates assessed diagnostic criteria rather than treating every instance of misuse as a disorder. Survey results also depend on self-reporting and coverage of the sampled population. (cdc.gov)\n\nOverdose surveillance uses death counts and mortality rates, commonly expressed per 100,000 population; age-adjusted rates permit comparisons between populations with different age structures. Opioid-involved deaths form a subset of all drug-overdose deaths: in 2023, approximately 105,000 Americans died from drug overdose, and nearly 80,000 deaths—about 76%—involved opioids. “Involved” does not mean that an opioid was the only substance contributing to death. A death involving both fentanyl and cocaine can appear in both substance categories, so category totals cannot simply be added. Death-certificate specificity, incomplete investigations, and reporting delays limit interpretation; provisional counts are revised as records arrive and investigations conclude. (cdc.gov)\n\nCDC describes three overlapping waves in United States opioid-overdose mortality. The first followed increased opioid prescribing during the 1990s, with deaths involving prescription opioids increasing from at least 1999; its statistical category includes natural and semisynthetic opioids and methadone. The second began in 2010 with rapidly increasing heroin-involved deaths. The third began in 2013 with increasing deaths involving synthetic opioids other than methadone, particularly illicitly manufactured fentanyl. These dates identify changes in national mortality patterns, not the first appearance of each drug or mutually exclusive periods. Prescription opioids, heroin, and synthetic opioids continued to coexist, and individual deaths could involve more than one category. (cdc.gov)\n\nUnited States regulation separates pharmaceutical approval from controlled-substance classification. The Food and Drug Administration evaluates opioid medicines within a benefit–risk framework that includes prescribed use and public-health consequences of inappropriate use, and continues safety surveillance after approval. Controlled-drug scheduling imposes a separate legal framework: morphine, oxycodone, methadone, and fentanyl are Schedule II substances under the Controlled Substances Act. State-run prescription drug monitoring programs collect controlled-prescription records to inform clinical practice and identify potentially hazardous prescribing patterns. Such records concern pharmaceutical dispensing, rather than constituting a comprehensive measure of illicit-drug exposure. (fda.gov)\n\nSafety labeling and public-health programs operate alongside these controls. On December 15, 2023, FDA announced final approval and implementation of opioid-analgesic labeling updates addressing risks and prescribing information. On March 29, 2023, it approved the first nonprescription naloxone product, a 4-mg nasal spray, changing access to an overdose-reversal medicine without changing the legal status of opioid analgesics. CDC’s Overdose Data to Action program funds health departments to connect fatal and nonfatal overdose surveillance with prevention activities, including improved data collection and locally targeted responses. (fda.gov)\n\nInternational access presents a different population-health problem. The World Health Organization report Left behind in pain, published in June 2023, documented unequal medical availability of morphine, including a 5- to 63-fold difference in estimated median consumption between high-income countries and lower-income country groups. Consumption also varied substantially among countries of similar wealth and did not consistently correspond to estimated medical need. Identified barriers included overly restrictive legislation, unreliable procurement and supply, inadequate services, insufficient training, and misconceptions about opioid medicines. These findings concern regulated medical access, including palliative care, rather than measuring nonmedical consumption or illicit supply. A country can therefore have insufficient morphine availability for patients despite the existence of illegal opioid markets. (who.int)"
    },
    {
      "heading": "Research Methods and Outstanding Scientific Questions",
      "text": "Receptor-binding experiments distinguish ligand recognition from receptor activation. Saturation assays use increasing concentrations of a labelled ligand to estimate binding affinity and available binding sites; competition assays measure displacement by another compound. Functional experiments instead measure responses such as G-protein coupling, inhibition of cyclic AMP production, or β-arrestin recruitment. In 2020, Tao Che and colleagues combined these approaches with conformation-selective nanobodies at the κ-opioid receptor. Nb6 stabilized an inactive state, whereas Nb39 stabilized an active-like state; dynorphin A showed approximately 200-fold higher affinity in the presence of Nb39 than Nb6. Bioluminescence resonance energy transfer also allowed the researchers to monitor nanobody association with receptors in living cells, linking binding measurements to conformational changes. (pmc.ncbi.nlm.nih.gov)\n\nStructural methods identify the molecular arrangements underlying these responses. Che and colleagues used X-ray crystallography to determine the κ-receptor–JDTic–Nb6 complex at 3.3 Å resolution, revealing an intracellular nanobody-binding site between transmembrane helices 5 and 6. Crystallography and cryo-electron microscopy, however, preferentially capture stabilized conformations rather than the complete range of receptor movements. In 2024, Jiawei Zhao, Matthias Elgeti, and colleagues used double electron–electron resonance and single-molecule fluorescence resonance energy transfer to examine μ-receptor dynamics. They distinguished a pre-activated conformation capable of binding G protein from a fully activated conformation that substantially reduced GDP affinity in the receptor–G-protein complex. These measurements connect ligand efficacy to transitions among receptor states, rather than simply to a single “active” structure. (pmc.ncbi.nlm.nih.gov)\n\nSignaling bias means that a ligand preferentially engages one signaling pathway over another relative to a reference ligand; low intrinsic efficacy means limited capacity to activate the receptor. The distinction depends critically on experimental design. An amplified G-protein assay can produce a large response to a weak agonist, while a less amplified β-arrestin assay produces little response to the same compound, creating apparent bias. Receptor abundance, response ceilings, and measurement timing further complicate comparisons. Alexander Gillis and colleagues reported in 2020 that oliceridine, PZM21, and SR-17018 had low intrinsic efficacy when assessed with assays designed to avoid restricted signal windows. Their measurements showed correlated efficacy across receptor activation, G-protein coupling, and β-arrestin recruitment, supporting partial agonism as an alternative explanation for these compounds’ reported profiles. (pubmed.ncbi.nlm.nih.gov)\n\nSeparating analgesia from respiratory depression, constipation, and other adverse effects remains a translational research problem. Proposed approaches include pathway-selective activation and manipulation of receptor conformations through allosteric sites. Gillis and colleagues’ antinociception and respiratory measurements supported low efficacy as an explanation for an improved experimental therapeutic window. Such cellular and animal results establish mechanistic possibilities, not demonstrated clinical safety: a favorable signaling profile does not itself show that a medicine causes fewer serious adverse events in humans. Conformation-selective probes likewise provide tools for testing hypotheses rather than proof of therapeutic benefit. (pubmed.ncbi.nlm.nih.gov)\n\nClinical uncertainties concern sustained pain relief, function, quality of life, individual prediction, and treatment retention. The evidence review underlying the CDC’s 2022 guideline found no placebo-controlled opioid trial assessing chronic-pain effectiveness at six months or longer, and no validated, reliable method for predicting individual benefit or serious harm. Randomized trials can compare assigned treatment strategies, while observational studies examine longer-term and uncommon outcomes but face confounding by illness severity and treatment selection. Retention studies also require attention to setting and follow-up: Yih-Ing Hser and colleagues’ 2014 secondary analysis involved 1,267 participants randomized to buprenorphine/naloxone or methadone for 24 weeks in nine treatment programs. It examined treatment completion and predictors of dropout, leaving longer-term continuity and applicability beyond those programs as separate questions. (cdc.gov)"
    }
  ],
  "links": [
    "morphine",
    "pain",
    "anesthesia",
    "palliative-care",
    "public-health",
    "pharmacology",
    "ligand",
    "cough",
    "brain",
    "molecular-recognition",
    "amino-acid",
    "protein",
    "central-nervous-system",
    "neuron",
    "neurotransmitter",
    "membrane-potential",
    "ion-channel",
    "constipation",
    "dopamine",
    "metabolism",
    "enzyme",
    "gene",
    "kidney",
    "surgery",
    "cancer",
    "quality-of-life",
    "rehabilitation",
    "randomized-controlled-trial",
    "nausea",
    "ethanol",
    "pregnancy",
    "diagnosis",
    "mortality-rate",
    "mental-health",
    "primary-health-care",
    "united-states",
    "world-health-organization",
    "epidemiology",
    "prevalence",
    "public-health-surveillance",
    "legislation",
    "x-ray-crystallography",
    "cryo-electron-microscopy",
    "experimental-design",
    "confounding"
  ],
  "sources": [
    {
      "title": "Opioid overdose",
      "url": "https://www.who.int/news-room/fact-sheets/detail/opioid-overdose/"
    },
    {
      "title": "Opioid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database",
      "url": "https://doi.org/10.2218/gtopdb/F50/2019.4"
    },
    {
      "title": "Receptors | IUPHAR - PEP",
      "url": "https://pharmacologyeducation.org/receptors/"
    },
    {
      "title": "Opioids | National Institute on Drug Abuse (NIDA)",
      "url": "https://www.drugabuse.gov/drugs-abuse/opioids"
    },
    {
      "title": "Community management of opioid overdose",
      "url": "https://www.afro.who.int/sites/default/files/2017-06/9789241548816_eng.pdf"
    },
    {
      "title": "Drugs of Abuse: A DEA Resource Guide, 2024 Edition",
      "url": "https://www.dea.gov/sites/default/files/2025-01/Narcotics-Drug-Fact-Sheet.pdf"
    },
    {
      "title": "Initiating Buprenorphine Treatment in the Emergency Department",
      "url": "https://nida.nih.gov/ed-buprenorphine"
    },
    {
      "title": "A Review of Opioids and Treatment of Opioid Dependence",
      "url": "https://nida.nih.gov/sites/default/files/review-of-opioids-and-treatment-of-opioid-dependence.pdf"
    },
    {
      "title": "What is Fentanyl? | Faces of Fentanyl",
      "url": "https://fof.dea.gov/what-is-fentanyl"
    },
    {
      "title": "Facts about Fentanyl",
      "url": "https://www.dea.gov/resources/facts-about-fentanyl?enableDeviceSpecificMedia=rvhv2&lang=en-US"
    },
    {
      "title": "FENTANYL",
      "url": "https://www.deadiversion.usdoj.gov/drug_chem_info/fentanyl.pdf"
    },
    {
      "title": "Morphine",
      "url": "https://cen.acs.org/articles/83/i25/Morphine.html"
    },
    {
      "title": "FDA Summary Review: NDA 207975",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207975Orig1s000SumR.pdf"
    },
    {
      "title": "Opium Poppy",
      "url": "https://museum.dea.gov/exhibits/online-exhibits/cannabis-coca-and-poppy-natures-addictive-plants/opium-poppy"
    },
    {
      "title": "Heroin Bottle",
      "url": "https://museum.dea.gov/museum-collection/collection-spotlight/artifact/heroin-bottle"
    },
    {
      "title": "Drugs of Abuse: A DEA Resource Guide, 2024 Edition",
      "url": "https://www.dea.gov/sites/default/files/2024-12/2024-Drugs-of-Abuse-508.pdf"
    },
    {
      "title": "Fentanyl Analogs",
      "url": "https://www.pnnl.gov/explainer-articles/fentanyl-analogs"
    },
    {
      "title": "Opiate receptor: demonstration in nervous tissue",
      "url": "https://pubmed.ncbi.nlm.nih.gov/4687585/"
    },
    {
      "title": "Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate",
      "url": "https://pubmed.ncbi.nlm.nih.gov/4516196/"
    },
    {
      "title": "Identification of two related pentapeptides from the brain with potent opiate agonist activity",
      "url": "https://pubmed.ncbi.nlm.nih.gov/1207728/"
    },
    {
      "title": "NOP receptor | Opioid receptors | IUPHAR/BPS Guide to PHARMACOLOGY",
      "url": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320"
    },
    {
      "title": "The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors",
      "url": "https://www.langenhan-lab.org/_files/ugd/4ffc5b_12e980a239174a2cba102c71246128a5.pdf"
    },
    {
      "title": "Opioid Peptides: Molecular Pharmacology, Biosynthesis, and Analysis, 70",
      "url": "https://www.govinfo.gov/content/pkg/GOVPUB-HE20-PURL-gpo71107/pdf/GOVPUB-HE20-PURL-gpo71107.pdf"
    },
    {
      "title": "Met]enkephalin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614&tab=summary"
    },
    {
      "title": "dynorphin A | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1620"
    },
    {
      "title": "The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors",
      "url": "https://research.edgehill.ac.uk/ws/files/85673681/bph.16177.pdf"
    },
    {
      "title": "Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation",
      "url": "https://pubmed.ncbi.nlm.nih.gov/1974052/"
    },
    {
      "title": "Localization and Regulation of Fluorescence-Labeled Delta Opioid Receptor, Expressed in Enteric Neurons of Mice",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4429902/"
    },
    {
      "title": "Opioid peptides and noradrenaline co-exist in large dense-cored vesicles from sympathetic nerve",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7145093/"
    },
    {
      "title": "Peptidases Prevent μ-Opioid Receptor Internalization in Dorsal Horn Neurons by Endogenously Released Opioids",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2464295/"
    },
    {
      "title": "Ligand-induced mu opioid receptor endocytosis and recycling in enteric neurons",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12763066/"
    },
    {
      "title": "Ligand-dependent G protein dynamics underlying opioid signaling efficacy",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12236782/"
    },
    {
      "title": "Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8863832/"
    },
    {
      "title": "Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8637575/"
    },
    {
      "title": "Functional couplings of the delta- and the kappa-opioid receptors with the G-protein-activated K+ channel",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7887943/"
    },
    {
      "title": "Opioid inhibition of N-type Ca2+ channels and spinal analgesia couple to alternative splicing",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2956429/"
    },
    {
      "title": "Molecular identification of bulbospinal ON neurons by GPER, which drives pain and morphine tolerance",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9797334/"
    },
    {
      "title": "Selective regulation of pain affect following activation of the opioid anterior cingulate cortex system.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/15996657/"
    },
    {
      "title": "Dose-dependent respiratory depression by remifentanil in the rabbit Parabrachial Nucleus/ Kölliker-Fuse Complex and preBötzinger Complex",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8489159/"
    },
    {
      "title": "Regulatory role of enteric mu and kappa opioid receptors in the release of acetylcholine and norepinephrine from guinea pig ileum",
      "url": "https://pubmed.ncbi.nlm.nih.gov/1975621/"
    },
    {
      "title": "DailyMed — MORPHINE SULFATE solution",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b86b6d-9a39-494c-bf65-f62e4cdc5807"
    },
    {
      "title": "Fentanyl Citrate Injection",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019101Orig1s060lbl.pdf"
    },
    {
      "title": "DailyMed — MORPHINE SULFATE tablet, film coated, extended release",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc3b491c-a206-3027-54f0-f87c0dd40a7f&version=1012"
    },
    {
      "title": "DailyMed — FENTANYL TRANSDERMAL patch, extended release",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e15a7e9b-8025-49dd-9a6d-bafcccf1959f"
    },
    {
      "title": "DailyMed — ACTIQ—fentanyl citrate lozenge",
      "url": "https://www.dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a"
    },
    {
      "title": "DailyMed — FENTANYL CITRATE injection",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58dcd3f7-e3d8-4929-a186-8f680a51ff11"
    },
    {
      "title": "DailyMed — METHADONE HYDROCHLORIDE tablet",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6984eb5a-57a3-4686-bc67-91bc3e7a531e"
    },
    {
      "title": "CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022",
      "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm"
    },
    {
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8249478/"
    },
    {
      "title": "Fentanyl Citrate Injection prescribing information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/016619s056lbl.pdf"
    },
    {
      "title": "Cancer Pain (PDQ®) – Health Professional Version",
      "url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq"
    },
    {
      "title": "Last Days of Life",
      "url": "https://www.cancer.gov/about-cancer/advanced-cancer/caregivers/planning/last-days-pdq"
    },
    {
      "title": "FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older",
      "url": "https://www.fda.gov/files/drugs/published/Drug-Safety-Communication--Opioid-Cough-and-Cold-Meds.pdf"
    },
    {
      "title": "Codeine not to be used in children below 12 years for cough and cold",
      "url": "https://www.ema.europa.eu/en/news/codeine-not-be-used-children-below-12-years-cough-cold"
    },
    {
      "title": "OxyContin (oxycodone hydrochloride) extended-release tablets: prescribing information, October 2021",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022272s047lbl.pdf"
    },
    {
      "title": "New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines",
      "url": "https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/new-safety-measures-announced-opioid-analgesics-prescription-opioid-cough-products-and"
    },
    {
      "title": "FDA Briefing Document",
      "url": "https://www.fda.gov/media/131025/download"
    },
    {
      "title": "Transcript of FDA Media Briefing on Codeine and Tramadol in Certain Children and Nursing Mothers",
      "url": "https://www.fda.gov/media/105059/download"
    },
    {
      "title": "FDA opioid prescribing information: Drug Abuse and Dependence",
      "url": "https://www.fda.gov/media/121182/download"
    },
    {
      "title": "CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9315909/"
    },
    {
      "title": "CREB (cAMP Response Element-Binding Protein) in the Locus Coeruleus: Biochemical, Physiological, and Behavioral Evidence for a Role in Opiate Dependence",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6793917/"
    },
    {
      "title": "Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26171718/"
    },
    {
      "title": "Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7983936/"
    },
    {
      "title": "TIP 63 — Medications for Opioid Use Disorder",
      "url": "https://library.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006.pdf"
    },
    {
      "title": "FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use",
      "url": "https://www.fda.gov/drugs/drug-safety-communications/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use"
    },
    {
      "title": "Opioid Use Disorder: Diagnosis",
      "url": "https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-diagnosis.html"
    },
    {
      "title": "About OUD",
      "url": "https://www.cdc.gov/overdose-prevention/hcp/training-modules/assessing-oud/page1196486.html"
    },
    {
      "title": "Medications to Treat Opioid Use Disorder",
      "url": "https://irp.nida.nih.gov/wp-content/uploads/2019/12/NIDA-Medications-to-treat-opioid-use-disorder_2018.pdf"
    },
    {
      "title": "Medications to Treat Opioid Use Disorder",
      "url": "https://nida.nih.gov/sites/default/files/21349-medications-to-treat-opioid-use-disorder_0.pdf"
    },
    {
      "title": "Opioid Use Disorder: Treating",
      "url": "https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html"
    },
    {
      "title": "Medication Treatment for Opioid Use Disorder in the Federally Qualified Health Center Setting",
      "url": "https://nida.nih.gov/nidamed-medical-health-professionals/science-to-medicine-medication-treatment-opioid-use-disorder/medication-treatment-opioid-use-disorder-in-federally"
    },
    {
      "title": "Substance Use Disorders: Statutes, Regulations, and Guidelines",
      "url": "https://www.samhsa.gov/substance-use/treatment/statutes-regulations-guidelines"
    },
    {
      "title": "Waiver Elimination (MAT Act)",
      "url": "https://www.samhsa.gov/substance-use/treatment/resources/mat-act"
    },
    {
      "title": "Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25919527/"
    },
    {
      "title": "Barriers to Broader Use of Medications to Treat Opioid Use Disorder",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK541389/"
    },
    {
      "title": "Difficulties in diagnosing narcotic overdoses in hospitalized patients",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8038463/"
    },
    {
      "title": "Opioid overdose: preventing and reducing opioid overdose mortality",
      "url": "https://cdn.who.int/media/docs/default-source/substance-use/opioid-overdose.pdf"
    },
    {
      "title": "Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10096213/"
    },
    {
      "title": "Community management of opioid overdose",
      "url": "https://www.who.int/publications/i/item/9789241548816"
    },
    {
      "title": "NARCAN (naloxone hydrochloride) nasal spray: prescribing information, revised March 2023",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411s007lbl.pdf"
    },
    {
      "title": "United States Dispensing Rate Maps",
      "url": "https://www.cdc.gov/overdose-prevention/data-research/facts-stats/us-dispensing-rate-maps.html"
    },
    {
      "title": "Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health",
      "url": "https://www.samhsa.gov/data/sites/default/files/reports/rpt47095/National%20Report/National%20Report/2023-nsduh-annual-national.htm"
    },
    {
      "title": "2023 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions",
      "url": "https://www.samhsa.gov/data/sites/default/files/reports/rpt47098/Methodological%20Summary%20and%20Definitions/2023-nsduh-method-summary-defs.htm"
    },
    {
      "title": "Understanding the Opioid Overdose Epidemic",
      "url": "https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html"
    },
    {
      "title": "Products - Vital Statistics Rapid Release - Provisional Drug Overdose Data",
      "url": "https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm"
    },
    {
      "title": "Opioid Medications",
      "url": "https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/opioid-medications"
    },
    {
      "title": "Preventing Opioid Use Disorder",
      "url": "https://www.cdc.gov/overdose-prevention/prevention/preventing-opioid-use-disorder.html"
    },
    {
      "title": "FDA approves safety labeling changes for opioid pain medicines",
      "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-safety-labeling-changes-opioid-pain-medicines"
    },
    {
      "title": "FDA Approves First Over-the-Counter Naloxone Nasal Spray",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray"
    },
    {
      "title": "Left behind in pain: Extent and causes of global variations in access to morphine for medical use and actions to improve safe access",
      "url": "https://www.who.int/publications/i/item/9789240075269"
    },
    {
      "title": "People with medical needs are “left behind in pain” reveals new report",
      "url": "https://www.who.int/news/item/16-06-2023-people-with-medical-needs-are--left-behind-in-pain--reveals-new-report"
    },
    {
      "title": "Nanobody-enabled monitoring of kappa opioid receptor states",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7052193/"
    },
    {
      "title": "Ligand efficacy modulates conformational dynamics of the µ-opioid receptor",
      "url": "https://www.nature.com/articles/s41586-024-07295-2"
    },
    {
      "title": "Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32234959/"
    },
    {
      "title": "Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32665252/"
    },
    {
      "title": "Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23961726/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}